These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34802966)

  • 1. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
    Venugopal B; Pillai M; Powles T; Savage P; Michael A; Fife K; Klair B; Perrot V; Szabados B
    Clin Genitourin Cancer; 2022 Feb; 20(1):94-94.e10. PubMed ID: 34802966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
    Nathan P; Venugopal B; Ali J; Allison J; Ceruso M; Charnley N; Griffiths R; Michael A; Moore K; Perrot V; Prendergast Á; Sharma A; Szabados B; Larkin J
    Clin Genitourin Cancer; 2024 Oct; 22(5):102141. PubMed ID: 39107157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
    Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
    Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
    Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
    Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.
    Waddell T; Fife K; Griffiths R; Sharma A; Dhokia P; Groves L; Hurst M; Tsang C; Sugrue D; McKenna S; Houghton J; Carroll R
    BMC Cancer; 2022 Jun; 22(1):617. PubMed ID: 35668384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
    Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
    Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
    J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.
    Schmidt E; Lister J; Neumann M; Wiecek W; Fu S; Vataire AL; Sostar J; Huang S; Marteau F
    Target Oncol; 2018 Apr; 13(2):205-216. PubMed ID: 29492762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
    Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
    Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
    Maruzzo M; Pierantoni F; Bortolami A; Palleschi D; Zivi A; Nicodemo M; Sartori D; De Vivo R; Zustovich F; Bimbatti D; Pastorelli D; Vultaggio GD; Soraru' M; Ballestrin M; Modonesi C; Randisi P; Barile C; Perri G; Basso U; Zagonel V
    Target Oncol; 2022 Jul; 17(4):467-474. PubMed ID: 35751733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
    Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
    Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
    Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
    Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
    Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
    Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
    Brown J; Harrow B; Marciniak A; McCarthy C; Houchard A; Cirneanu L; Protheroe A
    Drugs Real World Outcomes; 2024 Jun; 11(2):195-207. PubMed ID: 38265633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.